



# Jazz Is Committed to Removing Barriers to Access and Reimbursement

## JAZZCARES HELPS APPROPRIATE PATIENTS GET ACCESS TO DEFITELIO



JazzCares is **committed to helping patients get access to Defitelio** and **providing personalized support** throughout their treatment<sup>a</sup>:

- Understanding existing insurance coverage and benefits investigations
- Prior authorizations and appeals
- Coding and billing support
- Patient Assistance Program for eligible patients<sup>b</sup>
- Referrals to other financial assistance programs for eligible patients

## JAZZ ONCOLOGY BUSINESS MANAGERS



Jazz Oncology Business Managers **provide expertise and support:**

- Patient-specific issues
- Coding and billing support
- Access and reimbursement
- Purchasing, procurement, and distribution

To learn more about **JazzCares** support offerings, call **1-833-533-JAZZ (5299)**, Monday-Friday, 8 AM to 8 PM ET, click [here](#), or contact your **Oncology Business Manager**

<sup>a</sup>Insurance coverage and plans may vary. JazzCares provides general information only and is not a guarantee of any coverage or reimbursement outcome. All treatment decisions rest solely with the treating physician or qualified healthcare professional.

<sup>b</sup>Uninsured or underinsured patients who meet certain financial criteria may be eligible to receive Defitelio at no cost. Subject to financial and eligibility requirements and terms and conditions.

### NDC INFORMATION<sup>1</sup>

<b>Billing</b>	Single-patient-use vial: 200 mg/2.5 mL (concentration of 80 mg/mL) NDC 68727-800-01 <sup>c</sup>
<b>Ordering</b>	Carton (10 vials): NDC 68727-800-02

### ORDER THROUGH MCKESSON PLASMA AND BIOLOGICS<sup>d</sup>

<b>Phone/Fax</b>	877-625-2566/888-752-7626
<b>Online</b>	<a href="https://connect.mckesson.com">https://connect.mckesson.com</a>
<b>Email</b>	MPBOrders@mckesson.com
<b>Email (other requests)</b>	MPB@mckesson.com

**Based on the potential for rapid progression of VOD/SOS, it is advisable to have enough product on hand to treat an average-size patient for up to 48 hours.<sup>2,3</sup>**

<sup>c</sup>NDC number is for billing purposes only.

<sup>d</sup>Orders can be placed Monday through Friday, 9 AM to 7:30 PM ET. Overnight delivery is available for orders placed by 7:30 PM ET. For emergency orders after hours of service, call 1-877-625-2566 (24/7/365). Verify your institution has a contract before ordering; if not, contact McKesson or your Jazz Oncology Business Manager for information about setting up an account.

NDC=National Drug Code.

### Indication

Defitelio is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).

### IMPORTANT SAFETY INFORMATION

#### Contraindications

Defitelio is contraindicated in the following conditions:

- Concomitant administration with systemic anticoagulant or fibrinolytic therapy
- Known hypersensitivity to Defitelio or to any of its excipients

**Please see additional Important Safety Information on the next page and full [Prescribing Information](#).**

## CODING INFORMATION<sup>a</sup>

<b>Bone marrow transplant-associated DRG codes<sup>4</sup></b>	014: Allogeneic bone marrow transplant 016: Autologous bone marrow transplant with CC/MCC 017: Autologous bone marrow transplant without CC/MCC
<b>Hepatic VOD-associated DRG codes<sup>4</sup></b>	441: Disorders of liver except malignancy, cirrhosis, or alcoholic hepatitis with MCC 442: Disorders of liver except malignancy, cirrhosis, or alcoholic hepatitis with CC 443: Disorders of liver except malignancy, cirrhosis, or alcoholic hepatitis without CC/MCC
<b>Hepatic VOD-associated ICD-10-CM code<sup>5</sup></b>	K76.5: Hepatic veno-occlusive disease <sup>b</sup>
<b>J-codes:</b> If a J-code is needed, these codes may be applicable <sup>6</sup>	J3490: Unclassified drugs J9999: Not otherwise classified drug, antineoplastic J7599: Not otherwise classified drug, immunosuppressive

<sup>a</sup>Please confirm with the specific payer as they may require additional information prior to adjudication.

<sup>b</sup>Excludes Budd-Chiari syndrome (I82.0).<sup>5</sup>

CC=complication or comorbidity; DRG=diagnosis-related group; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification; MCC=major complication or comorbidity.

## IMPORTANT SAFETY INFORMATION (CONT.)

### Warnings and Precautions

#### Hemorrhage

Defitelio may increase the risk of bleeding in patients with VOD after HSCT. Do not initiate Defitelio in patients with active bleeding. Monitor patients on Defitelio for signs of bleeding. If bleeding occurs, withhold or discontinue Defitelio.

Concomitant systemic anticoagulant or fibrinolytic therapy may increase the risk of bleeding and should be discontinued prior to Defitelio treatment. Consider delaying Defitelio administration until the effects of the anticoagulant have abated.

#### Hypersensitivity Reactions

Hypersensitivity reactions including rash, urticaria, and angioedema have occurred in less than 2% of patients treated with Defitelio. One case of an anaphylactic reaction was reported in a patient who had previously received Defitelio. Monitor patients for hypersensitivity reactions, especially if there is a history of previous exposure. If a severe hypersensitivity reaction occurs, discontinue Defitelio, treat according to the standard of care, and monitor until symptoms resolve.

#### Most Common Adverse Reactions

The most common adverse reactions (incidence  $\geq 10\%$  and independent of causality) with Defitelio treatment were hypotension, diarrhea, vomiting, nausea, and epistaxis.

Please see full [Prescribing Information](#).

For more information on Defitelio, please visit [www.defitelio.com](http://www.defitelio.com).

**References:** 1. Defitelio (defibrotide sodium) injection. Prescribing Information. Jazz Pharmaceuticals, Inc. 2. Coppel JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. *Biol Blood Marrow Transplant*. 2010;16(2):157-168. 3. Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. *Br J Haematol*. 2015;168(4):481-491. 4. AAPC. DRG codes lookup. <https://www.aapc.com/codes/drg-codes-range/>. Accessed October 8, 2025. 5. Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. [https://ftp.cdc.gov/pub/Health\\_Statistics/NCHS/Publications/ICD10CM/2026/](https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2026/). Updated June 10, 2025. Accessed October 8, 2025. 6. Centers for Medicare & Medicaid Services. HCPCS Quarterly Update. <https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update>. Updated September 23, 2025. Accessed October 8, 2025.

Defitelio is a registered trademark of Jazz Pharmaceuticals, Inc.



©2025 Jazz Pharmaceuticals plc or its subsidiaries  
US-DEF-2500022 Rev1125

